Clinical Trial

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Trial in patients with newly diagnosed myeloma to evaluate the effect of isatuximab in induction therapy with lenalidomide/bortezomib/dexamethasone (RVd) and in lenalidomide maintenance treatment
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2018-07-31; most recent amendment 2026-01-30.
Status change: Recruiting → Active, Not Recruiting 2020-10-07
Status change: Not Yet Recruiting → Recruiting 2018-10-26
Trial Details
NCT Number NCT03617731
Lead Sponsor University of Heidelberg Medical Center
Conditions Multiple Myeloma
Enrollment 662 participants
Start Date 2018-10-18
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-02-03